Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 3Head & Neck 2Gastrointestinal 2Endocrine 1CNS 1Breast 1

Conditions

Small Cell Lung Carcinoma 1Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Neuroendocrine 1

Interventions

Specimen Handling 13Magnetic Resonance Spectroscopy 13lutetium Lu 177 dotatate 10cabozantinib 6Nivolumab 5X-Rays 4Ipilimumab 4Cisplatin 4pembrolizumab 3olaparib 3fludarabine 3Phantoms, Imaging 3Everolimus 3Etoposide 3Cyclophosphamide 3Carboplatin 3CTLA-4 Antigen 3gallium Ga 68 dotatate 2fluorodopa F 18 2aldesleukin 2Temozolomide 2Lutetium-177 2Lutetium 2Irinotecan 2Fluorodeoxyglucose F18 23-aminopyridine-2-carboxaldehyde thiosemicarbazone 2trametinib 1tipifarnib 1sodium thiosulfate 1selpercatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
budigalimab × Endocrine × 30 days × Clear all
NCT05599984 2026-05-07

Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors

AbbVie

Phase 1 Active not recruiting
288 enrolled
CNSEndocrineThoracic

Neoplasms, Central Nervous System Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡